Oncocross Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 31

Employees

  • Stock Symbol
  • 382150

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.29
  • (As of Friday Closing)

Oncocross General Information

Description

Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.

Contact Information

Website
www.oncocross.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Level 905, 7 Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul, Mapo-gu 05836
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
KRX
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences, Oncology
Corporate Office
  • Level 905, 7 Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul, Mapo-gu 05836
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncocross Stock Performance

As of 13-Nov-2026, Oncocross’s stock price is $2.29. Its current market cap is $27.9M with 12.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.29 $2.27 $1.55 - $9.88 $27.9M 12.2M 96.8K -$0.37

Oncocross Financials Summary

As of 30-Jun-2026, Oncocross has a trailing 12-month revenue of $273K.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 17,977 64,987 42,295
Revenue 273 260 786 70
EBITDA (3,297) (5,609) (4,678) (2,872)
Net Income (4,505) (6,274) (4,752) (3,223)
Total Assets 20,948 20,109 15,308 13,646
Total Debt 5,793 3,722 373 90
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncocross Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncocross‘s full profile, request access.

Request a free trial

Oncocross Patents

  • 103

    Total Documents Applications and Grants

  • Total Patents Families

  • 41

    Granted

  • 17

    Pending

  • Expiring in next 12 mo

Oncocross Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024291149-A1 Pharmaceutical composition comprising 1,3-benzodioxole derivative compound Pending 06-Jul-2023
EP-4740948-A1 Pharmaceutical composition comprising 1,3-benzodioxole derivative compound Pending 06-Jul-2023
WO-2025008783-A1 Pharmaceutical composition comprising 1,3-benzodioxole derivative compound Inactive 06-Jul-2023
WO-2023163475-A1 Anticancer composition containing ruboxistaurin Inactive 25-Feb-2022
US-20240318259-A1 Method for determining primary tumor site Pending 24-Sep-2021 C12Q1/6886
To view Oncocross’s complete patent history, request access »

Oncocross Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncocross Investments & Acquisitions (2)

Oncocross’s most recent deal was a Merger/Acquisition with oncoMASTER. The deal was made on 01-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
oncoMASTER 01-Jul-2026 Merger/Acquisition Laboratory Services (Healthcare)
Omix AI 08-Jan-2026 Corporate Biotechnology
To view Oncocross’s complete investments and acquisitions history, request access »

Oncocross ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Oncocross’s complete esg history, request access »

Oncocross Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
oncoMASTER Seoul, South Korea 2022

Oncocross FAQs

  • When was Oncocross founded?

    Oncocross was founded in 2015.

  • Where is Oncocross headquartered?

    Oncocross is headquartered in Seoul, South Korea.

  • What is the size of Oncocross?

    Oncocross has 31 total employees.

  • What industry is Oncocross in?

    Oncocross’s primary industry is Drug Discovery.

  • Is Oncocross a private or public company?

    Oncocross is a Public company.

  • What is Oncocross’s stock symbol?

    The ticker symbol for Oncocross is 382150.

  • What is the current stock price of Oncocross?

    As of 13-Nov-2026 the stock price of Oncocross is $2.29.

  • What is the current market cap of Oncocross?

    The current market capitalization of Oncocross is $27.9M.

  • What is Oncocross’s current revenue?

    The trailing twelve month revenue for Oncocross is $273K.

  • What is Oncocross’s annual earnings per share (EPS)?

    Oncocross’s EPS for 12 months was -$0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process